Evidence map›Paper›PMID 36838947›Full record

ReviewMolecules (Basel, Switzerland)2023

Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs.

Lozan Todorov, Irena Kostova

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. The radioactiveRSC advances · 2025
    Article
  7. Article
  8. Cytotoxic Organometallic Iridium(III) Complexes.Molecules (Basel, Switzerland) · 2025
    Review
  9. Article
  10. Recent Advances in Anticancer Research of Osmium and Rhodium Complexes.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lozan TodorovDepartment of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1504 Sofia, Bulgaria.ORCID 0000-0002-7230-8368
Irena KostovaDepartment of Chemistry, Faculty of Pharmacy, Medical University-Sofia, 1504 Sofia, Bulgaria.ORCID 0000-0001-6290-7327

Funding

Bulgarian National Science Fund, the Bulgarian National Recovery and Resilience Plan No. BG-RRP-2.004-0004-C01
6 · The paper itself

Abstract

Since the accidental discovery of the anticancer properties of cisplatin more than half a century ago, significant efforts by the broad scientific community have been and are currently being invested into the search for metal complexes with antitumor activity. Coordination compounds of transition metals such as platinum (Pt), ruthenium (Ru) and gold (Au) have proven their effectiveness as diagnostic and/or antiproliferative agents. In recent years, experimental work on the potential applications of elements including lanthanum (La) and the post-transition metal gallium (Ga) in the field of oncology has been gaining traction. The authors of the present review article aim to help the reader "catch up" with some of the latest developments in the vast subject of coordination compounds in oncology. Herewith is offered a review of the published scientific literature on anticancer coordination compounds of Pt, Ru, Au, Ga and La that has been released over the past three years with the hope readers find the following article informative and helpful.

Indexed as

Antineoplastic AgentsCoordination ComplexesRutheniumTransition ElementsPlatinumAntineoplastic AgentsCoordination ComplexesPlatinumRutheniumTransition Elementscancer researchcoordination complexesgalliumgoldlanthanumoncologyplatinumruthenium

Identifiers

PMID36838947
PMCPMC9965607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.